v3.26.1
Segment Information (Tables)
3 Months Ended
Mar. 31, 2026
Segment Reporting [Abstract]  
Schedule of Segment Reporting Information, by Segment
Significant segment expenses are included in the table below and represent direct and indirect research and development expenses by project for the three months ended March 31, 2026, and 2025 were as follows (in thousands):
Three Months Ended March 31,
20262025
Direct research and development expense:
Cadisegliatin6,507 918 
Other projects*
77 113 
Indirect research and development expense†2,394 1,799 
Total research and development expense$8,978 $2,830 
*
Includes HPP737 and azeliragon
Includes share-based compensation